Brian Frenzel - Los Altos, CaliforniaBrian Frenzel is a serial entrepreneur focusing in the biomedical products industry. His experience spans all industry sectors, including medical diagnostics, therapeutic devices, biologicals and pharmaceutical products. Over the span of a 25 year career in the industry, he has co-founded, financed and managed five biomedical companies and advised or served on the boards of directors of more than a dozen others.
Brian Frenzel’s enterprises have made discoveries and developed new products for the betterment of mankind addressing a large number of human diseases and conditions. In the 1980’s, Mr. Frenzel served on the front lines in the early war on HIV/AIDS and championed projects which led to the discovery of new hepatitis viruses. Later, Mr. Frenzel developed new products in woman’s healthcare to treat dysfunctional uterine bleeding and to diagnose preterm labor. He has engaged in a number of initiatives to discover and develop new products for neurodegenerative diseases, including stroke, Parkinson’s disease, Alzheimer’s disease, retinal disorders and multiple sclerosis. Mr. Frenzel has also worked in the orthopedic products arena to develop new products for the spine and to treat muscular/skeletal injury. Brian Frenzel’s’ current professional activities include serving as a member of the Band of Angels, a San Francisco Bay Area based angel investment group with over 125 members. He has been a member of the Band since 1998 and serves on its membership committee. The Band of Angels mentors and makes investments in early stage high tech, software, internet, clean tech and biomedical companies. In 2000, Mr. Frenzel became the President of the AnVent Group, a private investment and advisory firm that, like Band of Angels, funds and guides startup companies, in this case, solely in the biomedical products field. In 2006, Brian Frenzel joined the board of directors of Silicon Valley based SanBio, Inc. SanBio researches and develops cell therapies for neurodegenerative conditions. SanBio’s first product has recently entered human clinical studies in the United States to treat cognitive and motor disability resulting from ischemic stroke. In addition to his board duties, Brian Frenzel advises the company on its portfolio of other products under development, including those to treat muscular dystrophy, multiple sclerosis, Parkinson’s disease, conditions of the retina and spinal cord injury. Brian Frenzel’s current primary managerial endeavors are devoted to Tosk, Inc. of Santa Cruz, CA, where he has served as President and CEO since 2004. Tosk researches and develops new drugs to block the debilitating and potentially fatal side effects of cancer chemotherapeutics and radiation therapy. Tosk’s most advanced drug ameliorates mucositis, a painful and dose-limiting adverse effect of a number of cancer treatments. This product recently successfully completed the first stage of human clinical studies. A U.S. patent also recently issued covering this drug and related compounds and technologies, for which Mr. Frenzel was a co-inventor. |